# Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

> **NCT07237659** · PHASE1 · COMPLETED · sponsor: **Neutrolis** · enrollment: 36 (actual)

## Conditions studied

- SLE (Systemic Lupus)
- RA - Rheumatoid Arthritis

## Interventions

- **DRUG:** NTR1011

## Key facts

- **NCT ID:** NCT07237659
- **Lead sponsor:** Neutrolis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-04
- **Primary completion:** 2026-02-17
- **Final completion:** 2026-02-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07237659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07237659, "Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07237659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*